Investigating the Effects of Hyperoxia on Fractional Flow Reserve

This study is not yet open for participant recruitment.
Verified March 2014 by Bayside Health
Sponsor:
Information provided by (Responsible Party):
Bayside Health
ClinicalTrials.gov Identifier:
NCT01499316
First received: December 5, 2011
Last updated: March 6, 2014
Last verified: March 2014

December 5, 2011
March 6, 2014
March 2014
December 2014   (final data collection date for primary outcome measure)
Fractional flow reserve [ Time Frame: Duration of inpatient stay 2-3 days ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01499316 on ClinicalTrials.gov Archive Site
index of micro-vascular resistance [ Time Frame: Duration of inpatient stay 2-3 days ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Investigating the Effects of Hyperoxia on Fractional Flow Reserve
Investigating the Effects of Hyperoxia on Fractional Flow Reserve in Patients With Moderate Coronary Artery Disease

Coronary artery disease (CAD) is a condition which refers to the narrowing of the small blood vessels that supplies blood and oxygen to the heart. It is a common cause of chest-pain related symptoms and as a result of a 'heart attack'. In most cases, to assess the severity of the disease is to use coronary angiography, which is a medical imaging technique that uses contrast (a dye) and x-ray to show the blood-flow supply of the coronary arteries.

The optimal treatment for patients with symptomatic coronary disease is aggressive medical therapy. Current guidelines recommend patients with symptomatic CAD and severe disease on angiography undergo revascularisation therapy, which aims to restore blood flow to blocked arteries. This can be done by either percutaneous coronary intervention (feeding a small balloon or other device on a thin tube through blood vessels to the point of blockage and then inflate the balloon to open the artery), or coronary artery bypass grafting (open-heart surgery)2.

For many symptomatic patients who have only moderate disease on angiography, further functional testing is required to assess the extent of the blockage. This can be achieved by placing a pressure wire to the artery of interest, to determine the likelihood that the blockage impedes oxygen delivery to the heart muscle, known as the Fractional Flow Reserve (FFR)3. FFR is commonly performed at the Alfred hospital in the assessment of such patients. During an FFR procedure, further information regarding the health of the small arteries of the heart can be obtained with the calculation of the index of micro-vascular resistance (IMR),

Giving oxygen to patients with CAD is a common clinical practice, especially to all patients in the catheterisation laboratory whose had a 'heart attack' and often administered concurrently with light sedation during elective procedures.

Recently, however, the safety of routine supplemental oxygen in patients with CAD has been questioned5. A research study analysed the outcomes of three small randomised studies on oxygen in patients who experienced a 'heart attack', while suggestive of harm, the findings of the study remain inconclusive.

There may also be deleterious effects of supplemental oxygen, on more stable patients with CAD, who are not experiencing a 'heart attack'. Supplemental oxygen administered in the catheterisation laboratory to patients with stable CAD, has been shown to significantly reduce coronary artery blood flow and increase its resistance6-8. It has also been shown to reduce cardiac output and effect the relaxation phase of the heart cycle. Based on this data it is hypothesised that supplemental oxygen may affect FFR in patients with moderate CAD. The investigators therefore propose to undertake a study of the effects of supplemental oxygen on FFR in patients with moderate CAD.

The patients enrolled into the study will be scheduled for an elective normal contrast diagnostic or interventional procedure as part of their clinically-indicated care. Once a moderate blockage of the artery has been identified, FFR and IMR will be measured. During the first phase of the FFR study, the patient will breathe room air and have a blood test to measure their oxygen level (blood gas). There is a 3 minute washout period, followed by the second phase, whereby the patient will be given 100% oxygen for 10 minutes and have another blood gas measured.

The study will be conducted at Alfred Hospital with a total enrollment of 18 subjects. The estimated time to complete enrollment is 6-10 months.

Data collected on each patient will include demographics, medical history, vital signs (heart rate, blood pressure, height, and weight), usage of cardiovascular medications, pathology results and procedural records. Any adverse events or serious adverse events related to the study procedure will also be recorded.

Not Provided
Interventional
Not Provided
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Basic Science
Coronary Artery Disease
  • Procedure: High Flow oxygen
    10 minute shigh flow oxygen
  • Procedure: Room Air
    Room air breathing
  • Experimental: High Flow oxygen
    10 minute of 10/L min of inhaled oxygen with reservoir bag.
    Intervention: Procedure: High Flow oxygen
  • Experimental: Room Air
    Intervention: Procedure: Room Air
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Not yet recruiting
18
December 2014
December 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adults ≥ 18 years of age, AND
  • Undergoing elective coronary angiography
  • Evidence of moderate (40%-79%) stenosis, requiring further routine assessment with FFR.

Exclusion Criteria:

  • Acute coronary syndrome
  • Hypoxia with oxygen saturation measured on pulse oximeter < 94% with the patient breathing air
  • Altered conscious state
  • Evidence of left ventricular failure or cardiogenic shock
  • Unable to perform consent prior to procedure
  • Known hypersensitivity to adenosine
  • Sick sinus syndrome, second or third degree atrioventricular (A-V) block (except in patients with a functioning artificial pacemaker).
  • Chronic Obstructive lung disease COPD or asthma
  • Long QT syndrome
  • Severe hypotension
  • Concomitant use of dipyridamole
Both
18 Years to 90 Years
No
Not Provided
Australia
 
NCT01499316
426/11
No
Bayside Health
Bayside Health
Not Provided
Not Provided
Bayside Health
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP